A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML
Nour Sabiha Naji(Johns Hopkins University), Theodoros Karantanos(Johns Hopkins University), Amy E. DeZern(Johns Hopkins University), Brandy Perkins(Johns Hopkins University), Teodora Supeanu(Johns Hopkins University), Ivana Gojo(Johns Hopkins University), Bogdan C. Paun(Johns Hopkins University), Theodora Chatzilygeroudi(Johns Hopkins University), Suman Paul(Johns Hopkins University), Tushar D. Nichakawade(Howard Hughes Medical Institute), Gabriel Ghiaur(Johns Hopkins University), J. David Peske(Johns Hopkins University), Zanshé Thompson(University of South Carolina), Yoon‐Kyo An(Johns Hopkins University), Taha Ahmedna(Howard Hughes Medical Institute), Mark J. Levis(Sidney Kimmel Cancer Center), Styliani Karanika(Johns Hopkins University), Li Luo(Johns Hopkins University), Richard J. Jones(Johns Hopkins University), Xinghan Zeng(Johns Hopkins University), Bum Seok Lee(Johns Hopkins University), Evangeline Watson(Howard Hughes Medical Institute), Melanie Klausner(Johns Hopkins University), Linda Resar(Johns Hopkins University)
Cited by 1
Related Papers
VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION
|Transplantation|1987|914
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
|Oncogene|2013|879
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
|Nature|2012|745